Jump to content

Bezuclastinib

From Wikipedia, the free encyclopedia

Bezuclastinib
Clinical data
Other namesCGT-9486, PLX-9486
Legal status
Legal status
  • Investigational
Identifiers
  • 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC19H17N5O
Molar mass331.379 g·mol−1
3D model (JSmol)
  • CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C
  • InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)
  • Key:NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Bezuclastinib is an investigational new drug that is being evaluated for the treatment of solid tumors and systemic mastocytosis.[1][2] It acts as an inhibitor of KIT (a specific type of receptor tyrosine kinase).[3]

References

[edit]
  1. ^ "Bezuclastinib - Cogent Biosciences". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Farmer I, Radia DH (August 2024). "Systemic Mastocytosis: State of the Art". Current Hematologic Malignancy Reports. doi:10.1007/s11899-024-00737-8. PMID 39187708.
  3. ^ Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, et al. (September 2021). "Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial". JAMA Oncology. 7 (9): 1343–1350. doi:10.1001/jamaoncol.2021.2086. PMC 8267845. PMID 34236401.